Growth Metrics

Innoviva (INVA) Loans and Notes Receivables (2010 - 2012)

Innoviva posted quarterly Loans and Notes Receivables of $200000.0 for Q1 2012, up 100.0% on a QoQ basis from $100000.0 in Q4 2011.

Innoviva (INVA) has 3 years of Loans and Notes Receivables data on file, last reported at $200000.0 in Q1 2012.

  • For the quarter ending Q1 2012, Loans and Notes Receivables changed N/A year-over-year to $200000.0; the trailing twelve-month figure through Mar 2012 stood at $200000.0 (changed N/A YoY), and the FY2011 full-year result was $100000.0, down 81.17% from the prior year.
  • Loans and Notes Receivables for Q1 2012 stood at $200000.0, up from $100000.0 in the prior quarter.
  • Across five years, Loans and Notes Receivables topped out at $531000.0 in Q4 2010 and bottomed at $85000.0 in Q3 2011.
  • The 3-year median for Loans and Notes Receivables is $200000.0 (2011), against an average of $223200.0.
  • Peak annual rise in Loans and Notes Receivables reached 81.17% in 2011, while the deepest fall reached 81.17% in 2011.
  • A 3-year view of Loans and Notes Receivables shows it stood at $531000.0 in 2010, then slumped by 81.17% to $100000.0 in 2011, then soared by 100.0% to $200000.0 in 2012.
  • The last three Loans and Notes Receivables figures came in at $200000.0 (Q1 2012), $100000.0 (Q4 2011), and $85000.0 (Q3 2011), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Loans & Notes Receiv. (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Innoviva 1.60 Bn 992.84 Mn 75.83 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2012 200,000.00
Dec 31, 2011 100,000.00
Sep 30, 2011 85,000.00
Jun 30, 2011 200,000.00
Dec 31, 2010 531,000.00